Articles tagged with Helper T Cells
Researchers at MUSC found that Th17 cells can be expanded outside the body without losing effectiveness, providing a promising alternative to classic T cells used in adoptive immunotherapy. This breakthrough enables longer window periods for obtaining effective T cells via expansion outside the body.
Researchers at UF Health have found a way to expand and preserve certain cord-blood cells, known as Tregs, which modulate the immune system and prevent autoimmune diseases like Type 1 diabetes. This discovery has important implications for patients with the disease and could potentially be used as a treatment or preventive measure.
Researchers have discovered that the protein Myb plays a vital role in regulating the immune response, preventing overreaction and development of inflammatory diseases. The study found that Myb gives regulatory T cells the authority to control their function depending on the level of threat.
Researchers at Medical University of South Carolina found that inhibiting moesin reduces numbers of regulatory T cells, enabling the immune system to see and attack cancer. This could lead to new treatments for cancer and Treg-related immune disorders.
Scientists have discovered a network of chemical conversations between different types of cells that influence T cell specialisation in the immune system. They also identified genes involved in controlling antibody production during malaria infection, such as Galectin 1, which may be targeted by drugs to boost immunity.
Activated T-cells play a crucial role in promoting heart failure after a heart attack by attacking heart muscle tissue. Targeting specific T-cell subsets at defined stages of disease may represent a better therapeutic approach to improve heart failure outcomes.
A team from the University of Pennsylvania identified circulating helper immune cells in blood after an annual flu vaccine, tracking their contribution to antibody strength. The study found that these cells play a crucial role in antibody development and could inform future vaccine design.
Study findings reveal that IL-7 and IL-15 signal Th17 cells to chronically reside in the body, contributing to autoimmune disorders. The study suggests targeting these cytokines may lead to new therapies for chronic autoimmune diseases.
Researchers at Osaka University discovered a molecular mechanism underlying some autoimmune diseases. Satb1 regulates the development of regulatory T cells (Treg cells), which are essential for controlling hyperactive immune systems.
Researchers found that regulatory T cells in tumors have distinct features and differences compared to normal tissue, making them potential biomarkers or therapeutic targets. The study aims to improve cancer immunotherapies by targeting specific molecules expressed by these immune cells.
Researchers found that Th17 cells protect against the Trypanosoma cruzi parasite, which causes Chagas disease, by activating the immune system. This discovery offers a new approach to developing more protective vaccines for these diseases.
A team of researchers from ETH Zurich has discovered that a specific subset of blood cells - the regulatory T cells - can suppress lymphedema. This finding could help develop therapies to cure lymphedema by targeting inflammatory responses.
A recent study found a connection between follicular T helper cells and the development of type 1 diabetes. The cells were increased in frequency close to disease onset, particularly in children with multiple autoantibodies.
Research led by Catherine Hedrick found that removing ATP-binding cassette transporter G1 (ABCG1) from immune cells increases regulatory T cell production, decreases pro-inflammatory T cells, and reduces atherosclerotic lesions in mice. This suggests that therapies targeting ABCG1 could help control atherosclerosis.
Researchers found that individuals with high levels of broadly neutralizing antibodies have distinct immune system variations, including autoantibodies and altered T follicular helper cells. These findings support approaches to developing an HIV vaccine by modifying the immune system to mimic these conditions.
La Jolla Institute researchers reveal a powerful arm of the immune system that drives maturation of helper T cells. Their study identifies activin A as a key factor, which could lead to more potent vaccines and treatments for autoimmune diseases.
Researchers at Osaka University discovered that a group of T-cells with low FOXP3 expression, known as FOXP3-low T cells, facilitate cancer immunity in colorectal cancers. These findings suggest new potentials for treating CRCs via regulation of intestinal bacteria and defining patient groups. Intestinal bacteria induce inflammation in...
Researchers found that Candida-specific CD4 T cells are more susceptible to HIV infection and preferentially depleted earlier than CMV-specific cells. This sequential dysfunction may lead to the early loss of immune control over mucosal candidiasis in HIV-infected individuals.
New research identifies genetic variants associated with autoimmune diseases, providing potential therapeutic targets for treatments. The study mapped DNA regions regulating immune cells and found links to various autoimmune diseases.
A new cancer immunotherapy approach combines the power of tumor-fighting immune cells with fewer side effects. By converting T regulatory (Treg) cells into T effector (Teff) cells, this method targets tumors while protecting healthy tissues.
A study found that vaccination under the influence of estradiol enhances protection against genital herpes by shifting the immune response in the vaginal mucosa toward a more effective antiviral one. Estradiol accelerates and increases the response of T helper cells, promoting inflammation.
Researchers identified key signal TBK1 drives Tfh cell maturation, promoting precise immune response. ICOS regulates B cell activation and specificity through TBK1 association.
Researchers identified a critical immunotherapy target by marking dysfunctional regulatory T cells in glioblastoma multiforme patients. Anti-PD1 therapies may drive further regulatory T cell dysfunction, suggesting potential treatment benefits.
Researchers have identified a key role for a recently discovered immune cell in age-related inflammation and disease. The discovery sheds light on the mechanisms underlying these conditions and offers promising avenues for treatment.
Researchers from Johns Hopkins Medicine found that immune cells associated with allergies can promote healing of mouse muscle wounds when paired with biomaterial scaffolds. The discovery suggests a pivotal role for type 2 helper T cells in regulating the regenerative process, which may lead to novel strategies for tissue regeneration.
Researchers at TSRI isolated a unique Treg cell from a mouse model of type 1 diabetes and discovered it originates in the thymus, giving rise to two functional states: an nTreg with active FoxP3 and a pre-nTreg without. This discovery opens new avenues for developing novel therapies to prevent autoimmune diseases.
Researchers developed a gene therapy that programs T regulatory cells to protect transplanted tissues from rejection by the patient's immune system. This breakthrough could lead to new treatments for autoimmune diseases and open up possibilities for building genes for any disease where the immune system is overactive.
Researchers at the University of Bonn have identified an immune factor responsible for chronic viral infections. The study found that a molecule called tumor necrosis factor (TNF) impairs the immune response in these cases.
Researchers at University of Tsukuba discover that dying epithelial cells suppress proliferation of regulatory T cells, promoting inflammation. Beneficial bacteria in the gut can help Treg cell proliferation, but this effect is blocked by apoptotic epithelial cells.
A study reveals Sharpin's role in regulating survival of immunosuppressive T cells, essential for preventing autoimmune disease and cancer. Sharpin-deficient mice develop severe skin lesions and inflammation due to reduced Treg counts.
A new study published in Science found that viral infection during pregnancy can cause autism-like behaviors in mice offspring, characterized by deficits in social approach behavior and repetitive behaviors. Blocking the immune response with antibodies restored normal brain structure and function.
A new study published in Science suggests that food tolerance emerges over time in normal individuals due to specific populations of T cells. The research found that consumption of a normal diet stimulates gut cells that suppress rejection of food by the immune system, making children more susceptible to food allergies.
Researchers found that immune responses similar to viral infections in pregnant mice altered brain structure and caused behaviors associated with autism spectrum disorder. Blocking the action of a specific immune cell population restored normal behavior and brain structure in offspring.
Regulatory T cells use autophagy to maintain stability and function during their task of preventing autoimmune disease. Eliminating this process can lead to excessive cell death and loss of identity in the cells.
IL-17A and Th17 cells contribute to renal injury, which can lead to permanent scarring in kidneys. Blocking IL-17A/F signaling shows promise as a novel therapy for immune-mediated renal diseases.
A recent study from New York University has revealed a new mechanism to curb the activation of T helper 17 (Th17) cells, which play key roles in autoimmune and inflammatory diseases. The researchers discovered that a specific enzyme called DDX5 must first unfurl a snippet of genetic material called Rmrp to activate Th17 cells.
Recurrent Strep A infections may lead to autoimmune neuropsychiatric disorders in children through a previously unknown route. Immune cells triggered by the infection travel along odor-sensing neurons to reach the brain, causing inflammation and promoting neuroinflammation.
A study published in PLOS Pathogens suggests that blocking the PD-1/PD-L1 pathway can increase regulatory T cell numbers and virus production, while also boosting killer T cell proliferation. The researchers found that this approach may be beneficial for HIV-infected patients, but only when combined with antiretroviral treatment.
A new form of immunotherapy aims to protect insulin-producing cells using patients' own immune cells. The therapy, called regulatory T cells, was well-tolerated and durable in a Phase 1 clinical trial, supporting the development of a Phase 2 efficacy trial.
Aging mice with a new type of diabetes have high levels of immune cells called T regulatory cells in their fat tissue, leading to insulin resistance. Blocking these cells may hold the key to treating this age-related form of diabetes.
Scientists at Virginia Tech Carilion Research Institute have discovered that a small shift in environmental factors can change how a cell in the immune system matures. They examined how interleukin-15 influences gene expression patterns in T helper cells, finding that it promotes a different kind of immune response similar to decreased...
Researchers at NIH have developed a protein that awakens resting immune cells infected with HIV, facilitating their destruction. The protein, VRC07-αCD3, has shown promise in laboratory studies and animal trials, offering new hope for an HIV cure.
A study published in Immunity suggests that dietary fat impacts the severity and duration of autoimmune flare-ups in mice. Short-chain fatty acids were found to alleviate symptoms by promoting regulatory T cells, while long-chain fatty acids exacerbated inflammation.
Helper T cell proteins Oct1 and OCA-B work together to put immune response genes on standby, allowing for rapid activation upon re-exposure. This study sheds light on the molecular mechanisms controlling immunological memory in CD4+ cells.
A study published in Science reveals a mechanism that allows key immune system cells to restrain their more aggressive brother cells, protecting healthy tissue from assault. By targeting this genetic pathway with drugs, it may be possible to convert these cells into cancer-fighting cells.
A new Indiana University study reveals that sexual activity promotes types of immunity supporting conception. The research found higher levels of helper T cells and immunoglobulins in sexually active women compared to those who were abstinent.
KW-0761 efficiently eliminates Tregs from the blood of patients with lung or esophageal cancer, potentially augmenting the natural anticancer immune response. The study found a modest induction of antitumor immune responses and no marked clinical responses in patients treated with KW-0761 monotherapy.
Researchers at the University of Melbourne have captured images of immune cells responding to herpes simplex virus using state-of-the-art microscopy. The study reveals the dynamic choreography between killer T cells, helper T cells and dendritic cells as they work together to defeat an infection.
A new Penn study found that hydrogen sulfide regulates Treg cells by modifying a transcription factor called NFYB, leading to improved function and development of these regulatory cells. The study suggests potential therapeutic interventions for autoimmune diseases, cancer, and hypertension.
A recent study found that HIV virus can persist and continue to grow in patients receiving uninterrupted treatment for up to 14 years. This persistence occurs due to the virus's ability to hide inside blood cells responsible for immune response, copy itself, and automatically incorporate its genetic information into DNA.
A team of researchers at the La Jolla Institute for Immunology has identified LEF-1 and TCF-1 as master regulators that control the fate of T follicular helper cells. These transcription factors pre-program CD4+ T cells to respond to TFH induction signals, making them crucial for inducing a strong and lasting antibody response.
Researchers have discovered a potential new treatment for type 1 diabetes using the anti-inflammatory cytokine interleukin-35, which can reverse or cure the disease in mice models. The study also found that IL-35 concentrations are lower in T1D patients than healthy individuals.
Researchers found that mesenchymal stem cells alleviate inflammation and nephritis in mice with SLE, suggesting a potential treatment for severe autoimmune diseases. The study showed that MSCs suppress T helper cell development, which helps to slow disease progression.
Researchers found that immune tolerance can spontaneously recover after an infection-triggered rejection event, and hosts can accept subsequent transplants as soon as a week after. Regulatory T-cells play a key role in this process, acting as a 'brake' to prevent other immune cells from targeting the second transplant.
Regulatory T cells (Treg cells) play a critical role in shaping the immune response and maintaining self-tolerance. A recent study by LJI researchers identified a molecular pathway that maintains Treg cell stability and suppressive function, crucial for immune system balance. The discovery suggests that Treg cells may not be stable und...
Researchers found that oral thrush activates a mechanism in T-reg cells to transform inflammation-fighting cells into cells that allow the disease to flourish. The study may lead to new ways to fight diseases by identifying chronic inflammation and blocking inflammatory proteins.
Scientists at the University of Manchester have identified crucial molecules that allow regulatory T cells to function and cure active inflammation. This discovery could lead to improved therapies for autoimmune diseases such as type I diabetes, rheumatoid arthritis, and inflammatory bowel disease.
Research from the University of Southampton reveals that male HIV patients in rural South Africa reach low immunity levels required for antiretroviral treatment in less than a year, while women take up to three years. The study suggests that nutritional status and use of supplements may contribute to faster disease progression.
Researchers at Gladstone Institutes discovered a way to prevent MS onset in mice by blocking SIRT1, suggesting its role in autoimmune disorders. The treatment also shows promise for other diseases like type I diabetes.
Researchers at Université catholique de Louvain develop a new therapeutic agent that stimulates the immune system to target cancer cells by blocking immunosuppressive T-lymphocytes. This approach could lead to improved treatment efficiency for cancer patients and potentially treat other diseases with insufficient immunity.